News articles about Kite Pharma (NASDAQ:KITE) have trended somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kite Pharma earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.084848544629 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Can Biotech Keep Last Year’s Momentum Alive in 2018? – Nasdaq (nasdaq.com)
- Gene therapy approvals put need for new payer models front and center (bioworld.com)
- Bolder Novo Nordisk Emerges With $3.1 Billion Ablynx Pursuit – Bloomberg (bloomberg.com)
- UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer – GlobeNewswire (press release) (globenewswire.com)
Kite Pharma (KITE) remained flat at $$179.79 during trading on Friday. The company has a market capitalization of $10,280.00 and a PE ratio of -26.06. Kite Pharma has a twelve month low of $39.82 and a twelve month high of $179.95.
About Kite Pharma
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.